PT - JOURNAL ARTICLE AU - Klein, Julia AU - Yan, Xinyu AU - Johnson, Aubrey AU - Tomljanovic, Zeljko AU - Zou, James AU - Polly, Krista AU - Honig, Lawrence S. AU - Brickman, Adam M. AU - Stern, Yaakov AU - Devanand, D.P. AU - Lee, Seonjoo AU - Kreisl, William C. TI - Olfactory impairment is related to tau pathology and neuroinflammation in Alzheimer’s disease AID - 10.1101/2020.08.31.20183558 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.31.20183558 4099 - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20183558.short 4100 - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20183558.full AB - Background Olfactory impairment is evident in Alzheimer’s disease (AD), however, its precise relationships with clinical biomarker measures of tau pathology and neuroinflammation are not well understood.Objective To determine if odor identification performance measured with the University of Pennsylvania Smell Identification Test (UPSIT) is related to in vivo measures of tau pathology and neuroinflammation.Methods Participants were selected from an established research cohort of adults aged 50 and older who underwent neuropsychological testing, brain MRI, and amyloid PET. Fifty-four participants were administered the UPSIT. Forty-one underwent 18F-MK-6240 PET and fifty-three underwent 11C-PBR28 PET to measure tau pathology and neuroinflammation, respectively. Twenty-three participants had lumbar puncture to measure CSF concentrations of total tau (t-tau), phosphorylated tau (p-tau) and β-amyloid (Aβ42).Results Low UPSIT performance was associated with greater18F-MK-6240 binding in medial temporal cortex, hippocampus, middle/inferior temporal gyri, inferior parietal cortex and posterior cingulate cortex (p < 0.05). Similar relationships were seen for 11C-PBR28. These relationships were primarily driven by amyloid-positive participants. Lower UPSIT performance was associated with greater CSF concentrations of t-tau and p-tau (p < 0.05). Amyloid status and cognitive status exhibited independent effects on UPSIT performance (p < 0.01).Conclusions Olfactory identification deficits are related to extent of tau pathology and neuroinflammation, particularly in those with amyloid pathophysiology. The independent association of amyloid-positivity and cognitive impairment with odor identification suggests that low UPSIT performance may be a marker for AD pathophysiology in cognitive normal individuals, although impaired odor identification is associated with both AD and non-AD related neurodegeneration.NCT Registration Numbers: NCT03373604; NCT02831283Competing Interest StatementAdam M. Brickman- Consultant: Regeneron Pharmaceuticals, Cognition Therapeutics; Equity: Mars Holding Limited Lawrence S. Honig- Consultant: Cortexyme, Eisai, Medscape, Prevail; Research Grants: Abbvie, Alector, Biogen, Genentech, Eli Lilly, Roche D.P Devanand- Consultant: Acadia, BXcel, Corium, Genentech, Grifols William C. Kreisl- Consultant for Cerveau Technologies. However, Cerveau was not involved in the design or execution of this study or in the interpretation of the results.Clinical TrialNCT02831283 NCT03373604Funding StatementThis research was funded by National Institute of Aging grants K23AG052633, R01AG026158, R01AG062578 and R56AG034189. Support for this study came from NIA grant T35AG044303 and the Columbia University Alzheimers Disease Research Center (P50AG008702). Data collection and sharing for this project was supported by the Washington Heights-Inwood Columbia Aging Project (WHICAP, P01AG07232, R01AG037212, RF1AG054023). We acknowledge the WHICAP study participants and the WHICAP research and support staff for their contributions to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Columbia University Irving Medical Center Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data will be made available upon reasonable request to qualified investigators. William C. Kreisl takes full responsibility for the data, the analyses and interpretation, and the conduct of the research. He has full access to all of the data and has the right to publish any and all data separate and apart from any sponsor.